Sign In
Free Newsletter
AtlantiCare gets $1M gift for stroke, neuroscience care
The gift from the Lees family to AtlantiCare will expand stroke and neuroscience care, staffing, patient capacity and emergency response technology.
FDA approves J&J’s Caplyta as add-on depression drug
Johnson & Johnson acquired the treatment as part of its $14.6 billion acquisition of Bedminster-based Intra-Cellular, which closed in April.
Novartis’ $12B Avidity acquisition to expand neuroscience pipeline
The play for San Diego-based Avidity Biosciences will add RNA therapeutics that target rare genetic neuromuscular diseases.
Bristol Myers Squibb closes $14B Karuna deal
The "acquisition recognizes the enormous potential of KarXT," the Boston-based target's potential first-in-class treatment for schizophrenia in adults.
Bristol Myers Squibb says billion-dollar acquisitions will enhance neuroscience, cancer care
The biopharmaceutical company's play for Karuna Therapeutics will help it harness the "tremendous opportunities in neuroscience," while the addition of RayzeBio Inc. is set to bolster its "increasingly diversified oncology portfolio."
Jersey Shore University Medical Center to offer ‘first-in-the-world’ brain tech
This fall, the Dr. Robert H. and Mary Ellen Harris ZAP-X Center for Noninvasive Neurosurgery at the Hackensack Meridian Neuroscience Institute at the Neptune facility will debut a combination of equipment that aims to reduce time from diagnosis to treatment.
